Stay updated on DONIMI Clinical Trial: Neoadjuvant Domatinostat, Nivolumab, Ipilimumab
Sign up to get notified when there's something new on the DONIMI Clinical Trial: Neoadjuvant Domatinostat, Nivolumab, Ipilimumab page.

Latest updates to the DONIMI Clinical Trial: Neoadjuvant Domatinostat, Nivolumab, Ipilimumab page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page shows a new revision label 'Revision: v3.3.3' and removes the 'HHS Vulnerability Disclosure' item along with the older 'Revision: v3.3.2' note; these are cosmetic changes that do not impact the trial information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedRevision v3.3.2 was added to the history and revision v3.3.1 was removed; no study data or primary page content appears to be affected.SummaryDifference0.1%

- Check40 days agoChange DetectedA new revision entry v3.3.1 was added and an earlier revision v3.2.0 was removed from the Record History.SummaryDifference0.1%

- Check47 days agoChange DetectedRemoved the government funding/operating status notice, so the page no longer displays the banner about potential delays and links to cc.nih.gov and opm.gov. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check61 days agoChange DetectedTwo new versions (2023-11-14 and 2025-03-07) were added to the Record History, capturing updates to Recruitment Status, Study Status, and Contacts/Locations.SummaryDifference0.1%

- Check90 days agoChange DetectedAdded a government-operating-status notice and a new version tag (v3.2.0); removed the old version tag (v3.1.0).SummaryDifference12%

Stay in the know with updates to DONIMI Clinical Trial: Neoadjuvant Domatinostat, Nivolumab, Ipilimumab
Enter your email address, and we'll notify you when there's something new on the DONIMI Clinical Trial: Neoadjuvant Domatinostat, Nivolumab, Ipilimumab page.